±Þ¼º ¹éÇ÷º´ ȯÀÚ¿¡¼ °üÇØ À¯µµ ÈÇÐ ¿ä¹ýÈÄ °ú¸³±¸ Áý¶ô ÃËÁøÀÎÀÚ(Grnulocyte Colony-Stimulating Factor, Filgrastim)ÀÇ Åõ¿© È¿°ú
Granulocyte Colony-Stimulating Factor(G-CSF, Filgastrim)in Acute Leukemia after Remission Induction Chemotheraphy
¼Ò¼Ó »ó¼¼Á¤º¸
¼Ã¶¿ø
±è¼º¹è/±è»óÈñ/俵¶õ/µµº´¼ø/±è»óÀ§/¾È¸íÁÖ/À̱ÔÇü/ÀÌÁ¤½Å
KMID : 0360319940260030431
Abstract
Objectives
@EN Colony stimulating factors have been shown to accelerate recovery from severe neutropenia after intensive chemotherapy. To prove its clinical effectiveness, we conducted controlled study to administer G-CSF in acute leukemia after induction
chemotherapy.
@ES Methods:
@EN Forty patients with newly diagnosed and relapsed or refractory acute leukemia after remission induction chemotherapy were randomly assigned to one of two groups (20 G-CSF treated group, 20 control group). Treatment with G-CSF(200 ug/§³/d) was
started 48 hours after the and of chemotherapy and continued until the neutrophil count rose above 1,500/§§.
@ES Results:
@EN treatment with G-CSF shortened neutropenic period after chemotherapy, i.e., median duration of neutrophil counts less than 1,000/§§ was 21 days in control group and 12 days in G-CSF treated group. The incidence of infection was 80%in control
group,
70% in G-CSF treated group, but it did not show any statistically significant difference. Microbiologically documented infection was 40% in control group, 20% in G-CSF treated group. Febrile periods and duration of antibiotic administration were
decreased to 7 days and 18 days respectively. In G-CSF treated group, two patients reported mild bone pain. There was no evidence that G-CSF could increase remission duration and survival.
@ES Conclusion:
@EN It appears that recombinant G-CSF is safe and useful in neutropenic patients after intensive chemotherapy, accelerating neutrophil recovery and thereby reducing the incidence of documented infection and duration of antibiotic administration.
Å°¿öµå
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸